- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06045507
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
April 19, 2024 updated by: Merck Sharp & Dohme LLC
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8527 Once Monthly in Participants at Low-Risk for HIV-1 Infection
This double-blind, placebo-controlled study is designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1) infection.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
350
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Toll Free Number
- Phone Number: 1-888-577-8839
- Email: Trialsites@merck.com
Study Locations
-
-
-
Haifa, Israel, 3109601
- Active, not recruiting
- Rambam Health Care Campus ( Site 0003)
-
Jerusalem, Israel, 9112001
- Active, not recruiting
- Hadassah Medical Center ( Site 0002)
-
Ramat Gan, Israel, 5265601
- Active, not recruiting
- Sheba Medical Center ( Site 0001)
-
-
-
-
Free State
-
Bloemfontein, Free State, South Africa, 9301
- Recruiting
- Josha Research ( Site 0023)
-
Contact:
- Study Coordinator
- Phone Number: +27825724468
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2092
- Recruiting
- Helen Joseph Hospital ( Site 0024)
-
Contact:
- Study Coordinator
- Phone Number: +27834158967
-
Johannesburg, Gauteng, South Africa, 2001
- Recruiting
- Wits RHI-Wits RHI Ward 21 Clinical Research site ( Site 0027)
-
Contact:
- Study Coordinator
- Phone Number: +27728086113
-
-
Kwazulu-Natal
-
Ladysmith, Kwazulu-Natal, South Africa, 3370
- Recruiting
- Qhakaza Mbokodo Research Clinic ( Site 0026)
-
Contact:
- Study Coordinator
- Phone Number: +27824588969
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7925
- Recruiting
- Desmond Tutu Health Foundation ( Site 0021)
-
Contact:
- Study Coordinator
- Phone Number: 27214066964
-
-
-
-
California
-
North Hollywood, California, United States, 91606
- Active, not recruiting
- Velocity Clinical Research, North Hollywood ( Site 0054)
-
San Francisco, California, United States, 94102
- Recruiting
- Bridge HIV- San Francisco Department of Public Health ( Site 0042)
-
Contact:
- Study Coordinator
- Phone Number: 415-793-8877
-
-
Florida
-
Hallandale Beach, Florida, United States, 33009
- Recruiting
- Velocity Clinical Research, Hallandale Beach ( Site 0052)
-
Contact:
- Study Coordinator
- Phone Number: 954-243-0088
-
Immokalee, Florida, United States, 34142
- Recruiting
- Community Medical Care Center ( Site 0056)
-
Contact:
- Study Coordinator
- Phone Number: 239-657-5800
-
-
Maryland
-
Rockville, Maryland, United States, 20854
- Recruiting
- Velocity Clinical Research, Rockville ( Site 0048)
-
Contact:
- Study Coordinator
- Phone Number: 301-762-5020
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Fenway Health ( Site 0043)
-
Contact:
- Study Coordinator
- Phone Number: 617-927-6087
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Recruiting
- Albuquerque Clinical Trials, Inc. ( Site 0044)
-
Contact:
- Study Coordinator
- Phone Number: 505-224-7407
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0041)
-
Contact:
- Study Coordinator
- Phone Number: 412-320-1904
-
-
Texas
-
Dallas, Texas, United States, 75208
- Recruiting
- Prism Health North Texas, Oak Cliff Health Center ( Site 0045)
-
Contact:
- Study Coordinator
- Phone Number: 214-673-9463
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Fred Hutchinson Cancer Center - The Seattle HIV Vaccine Trials Unit ( Site 0057)
-
Contact:
- Study Coordinator
- Phone Number: 206-520-4268
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test result before randomization
- Has low-risk of HIV infection
- Females: is not pregnant or breastfeeding and is either not a participant of childbearing potential (POCBP) OR is a POCBP and uses an acceptable contraception or is abstinent from penile-vaginal intercourse
Exclusion Criteria:
- Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator
- Has an active diagnosis of hepatitis due to any cause, including active hepatitis B (HBV) infection (defined as HBsAg-positive) or hepatitis C virus (HCV) infection (defined as detectable HCV ribonucleic acid [RNA])
- Prior use of MK-8527 or islatravir (MK-8591)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MK-8527 Low Dose QM
Participants receive oral MK-8527 low dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
|
MK-8527 capsule
|
Experimental: MK-8527 Medium Dose QM
Participants receive oral MK-8527 medium dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
|
MK-8527 capsule
|
Experimental: MK-8527 High Dose QM
Participants receive oral MK-8527 high dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
|
MK-8527 capsule
|
Placebo Comparator: Placebo to MK-8527
Participants receive oral placebo matched to MK-8527 QM for 6 months, followed by an 8-week blinded safety follow-up period.
|
Placebo capsule matched to MK-8527
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With ≥1 Adverse Event (AE)
Time Frame: Up to ~28 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
|
Up to ~28 weeks
|
Number of Participants Discontinuing From Study Therapy Due to AE
Time Frame: Up to ~20 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
|
Up to ~20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Plasma Concentration-Time Curve From Dosing to Last Measurable Concentration (AUC0-last) of MK-8527
Time Frame: Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose
|
The AUC0-last of MK-8527 will be determined.
|
Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose
|
Maximum Plasma Concentration (Cmax) of MK-8527
Time Frame: Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose
|
The Cmax of MK-8527 will be determined.
|
Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 8, 2023
Primary Completion (Estimated)
February 18, 2025
Study Completion (Estimated)
February 18, 2025
Study Registration Dates
First Submitted
September 13, 2023
First Submitted That Met QC Criteria
September 13, 2023
First Posted (Actual)
September 21, 2023
Study Record Updates
Last Update Posted (Actual)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 19, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8527-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on MK-8527
-
Merck Sharp & Dohme LLCNot yet recruiting
-
Merck Sharp & Dohme LLCCompletedHuman Immunodeficiency VirusRomania, South Africa
-
Merck Sharp & Dohme LLCCompletedHuman Immunodeficiency Virus | AIDS VirusRomania
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCCompletedType 2 Diabetes Mellitus
-
Merck Sharp & Dohme LLCCompletedHypertension | Isolated Systolic Hypertension (ISH)
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedHepatitis C Virus Infection